12/22
07:02 am
legn
Here is Why Legend Biotech (LEGN) Offers Such Promising Upside [Yahoo! Finance]
Medium
Report
Here is Why Legend Biotech (LEGN) Offers Such Promising Upside [Yahoo! Finance]
12/17
09:06 am
legn
Legend Biotech (NASDAQ:LEGN) was given a new $74.00 price target on by analysts at Cantor Fitzgerald.
Low
Report
Legend Biotech (NASDAQ:LEGN) was given a new $74.00 price target on by analysts at Cantor Fitzgerald.
12/17
08:43 am
legn
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/17
08:00 am
legn
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/12
12:00 pm
legn
Legend Biotech (NASDAQ:LEGN) was given a new $50.00 price target on by analysts at Morgan Stanley.
Low
Report
Legend Biotech (NASDAQ:LEGN) was given a new $50.00 price target on by analysts at Morgan Stanley.
12/11
05:31 pm
legn
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
Medium
Report
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
12/11
05:31 pm
legn
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
Medium
Report
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
12/11
11:48 am
legn
Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects [Yahoo! Finance]
Low
Report
Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects [Yahoo! Finance]
12/9
04:25 pm
legn
Legend Biotech (NASDAQ:LEGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/8
11:02 am
legn
Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/8
08:13 am
legn
Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/6
02:00 pm
legn
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
Medium
Report
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
11/26
07:03 am
legn
Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/25
01:53 pm
legn
Legend Biotech (NASDAQ:LEGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
08:51 am
legn
William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns [Yahoo! Finance]
Low
Report
William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns [Yahoo! Finance]
11/22
07:28 am
legn
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
Medium
Report
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
11/21
05:32 pm
legn
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
Medium
Report
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
11/19
06:45 am
legn
Breakthrough Properties and Eli Lilly and Company Partner to Bring Lilly Gateway Labs to Newly-Developed 2300 Market Street in Philadelphia
Medium
Report
Breakthrough Properties and Eli Lilly and Company Partner to Bring Lilly Gateway Labs to Newly-Developed 2300 Market Street in Philadelphia
11/14
10:23 am
legn
LAST CALL: Join Nobel Laureate & Global Leaders to Explore the Next Era of Cell & Gene Therapy in London
Low
Report
LAST CALL: Join Nobel Laureate & Global Leaders to Explore the Next Era of Cell & Gene Therapy in London
11/13
04:04 pm
legn
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at Barclays PLC from $94.00 to $90.00. They now have an "overweight" rating on the stock.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at Barclays PLC from $94.00 to $90.00. They now have an "overweight" rating on the stock.
11/13
12:56 pm
legn
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at Royal Bank Of Canada from $75.00 to $74.00. They now have an "outperform" rating on the stock.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at Royal Bank Of Canada from $75.00 to $74.00. They now have an "outperform" rating on the stock.
11/13
12:36 pm
legn
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia [Yahoo! Finance]
Low
Report
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia [Yahoo! Finance]
11/13
12:08 pm
legn
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
Low
Report
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
11/13
09:36 am
legn
Legend Biotech (NASDAQ:LEGN) had its price target raised by analysts at Cantor Fitzgerald from $66.00 to $75.00. They now have an "overweight" rating on the stock.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its price target raised by analysts at Cantor Fitzgerald from $66.00 to $75.00. They now have an "overweight" rating on the stock.
11/12
12:54 pm
legn
Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript [Seeking Alpha]